Home > Insider Trading > Filing (0001213900-24-016240)

Filing Details

Accession Number:: 0001213900-24-016240
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2024-02-22 18:32:25
Reporting Period:: 2024-02-20

Accepted Time:: 2024-02-22 18:32:25
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1821586	Moonlake Immunotherapeutics	MLTX	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1920553	Kristian Reich	C/O Moonlake Immunotherapeutics Dorfstrasse 29 Zug V8 6300	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Class A Ordinary Shares, Par Value $0.0001 Per Share	Disposition	2024-02-20	10,000	$57.45	2,987,483	No	4	S	Indirect	See footnote.
Class A Ordinary Shares, Par Value $0.0001 Per Share	Disposition	2024-02-20	10,000	$57.43	100,071	No	4	S	Direct
Class A Ordinary Shares, Par Value $0.0001 Per Share	Disposition	2024-02-21	509	$55.31	2,986,974	No	4	S	Indirect	See footnote.
Class A Ordinary Shares, Par Value $0.0001 Per Share	Disposition	2024-02-21	569	$55.30	99,502	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Indirect	See footnote.
No	4	S	Direct
No	4	S	Indirect	See footnote.
No	4	S	Direct

Footnotes

This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on October 16, 2023.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.06 to $59.09. Upon request by the staff of the U.S. Securities and Exchange Commission (the "Commission"), the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
Represents the ordinary shares of the Issuer owned by JeruCON Beratungsgesellschaft mbH. Dr. Reich directly (whether through ownership or position) or indirectly through one or more intermediaries, may be deemed for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, to be the indirect beneficial owner of the ordinary shares owned by JeruCON Beratungsgesellschaft mbH.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.14 to $59.09. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.225 to $55.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $55.15 to $55.33. Upon request by the staff of the Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.